Azitra (AZTR) Receivables - Other (2022 - 2023)
Azitra (AZTR) posted Receivables - Other of $90000.0 for Q4 2023, down 79.55% on a QoQ basis from $440000.0 in Q2 2023, and down 48.57% year-over-year from $175000.0 in Q4 2022.
Azitra (AZTR) Receivables - Other (2022 - 2023) Analysis & Trends
Azitra's Receivables - Other history runs 2 years deep, the most recent figure standing at $90000.0 for Q4 2023.
- Quarterly Receivables - Other fell 48.57% year-over-year to $90000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $90000.0 (down 48.57% YoY) and the FY2023 annual result came in at $90000.0, down 48.57% from the prior year.
- Receivables - Other was $90000.0 for Q4 2023 at Azitra, down from $440000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $440000.0 in Q2 2023 and bottomed at $90000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 90,000.00 |
| Dec 31, 2023 | 90,000.00 |
| Jun 30, 2023 | 440,000.00 |
| Jun 30, 2023 | 440,000.00 |
| Dec 31, 2022 | 175,000.00 |
| Dec 31, 2022 | 175,000.00 |